AstraZeneca Plc's COVID-19 vaccine is effective against Delta and Kappa variants, which were first identified in India, the company said on Tuesday, citing a study.
The study by the Oxford University investigated the ability of monoclonal antibodies in blood from recovered people and from those vaccinated to neutralize the Delta and Kappa variants, the statement said.
Last week, an analysis by the Public Health England (PHE) showed that vaccines made by Pfizer Inc and AstraZeneca offer high protection of more than 90% against hospitalization from the Delta variant.
The latest Oxford study results are built on the recent analysis by PHE, the company said.
The Delta variant is becoming the globally dominant version of the disease, the World Health Organization's chief scientist said on Friday.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
Failure of AstraZeneca Trial Big Blow For Anti-Addiction Drugs: Report The Science Behind Long COVID: Understanding The Persistent Presence Of SARS-CoV-2 Proteins New XEC Covid Variant Spreads To 27 Countries, Here's What We Know So Far Bengaluru Techie Loses Rs 11.8 Crore After "Digital Arrest" 'Was Ahead Of His Time': Professor On Trump's Indian-Origin Pick For AI "Daughter Doesn't Know Her Mother's Dead": 'Pushpa 2' Stampede Victim's Husband Parts Of Delhi Face Water Shortage As Ammonia Levels Rise In Yamuna Navy's Warship INS Tushil Docks In London On Maiden Operational Deployment "It Pains My Heart...": PM Cites Germany, Lanka Attacks At Christmas Event Track Latest News Live on NDTV.com and get news updates from India and around the world.